Table 2.
Positive response to ≥1 and ≥12 pneumococcal vaccine serotype by baseline medication use (as-treated population)
| Baseline medication subgroup | Pre-belimumab cohort N = 34 | Belimumab-concurrent cohort N = 45 |
|---|---|---|
| Number of patients responding to ≥1 pneumococcal vaccine serotype, n/N (%) | ||
| Antimalarial use | ||
| Yes | 26/27 (96.3) | 36/37 (97.3) |
| No | 6/6 (100.0) | 4/4 (100.0) |
| Corticosteroid dose | ||
| >0 to ≤7.5 mg/day | 21/22 (95.5) | 21/22 (95.5) |
| >7.5 mg/day | 11/11 (100.0) | 19/19 (100.0) |
| Immunosuppressive use | ||
| Any | 16/17 (94.1) | 17/18 (94.4) |
| None | 16/16 (100.0) | 23/23 (100.0) |
| Number of patients responding to ≥12 pneumococcal vaccine serotype, n/N (%) | ||
| Antimalarial use | ||
| Yes | 23/27 (85.2) | 28/37 (75.7) |
| No | 4/6 (66.7) | 4/4 (100.0) |
| Corticosteroid dose | ||
| >0 to ≤7.5 mg/day | 17/22 (77.3) | 17/22 (77.3) |
| >7.5 mg/day | 10/11 (90.9) | 15/19 (78.9) |
| Immunosuppressive use | ||
| Any | 12/17 (70.6) | 13/18 (72.2) |
| None | 15/16 (93.8) | 19/23 (82.6) |